New PET scan could match breast cancer patients to the right drug

NCT ID NCT06830382

First seen Nov 20, 2025 · Last updated May 09, 2026 · Updated 22 times

Summary

This study is testing a new type of PET scan that looks for a protein called HER2 on breast cancer cells. The goal is to see if this scan can better predict which patients with advanced breast cancer will benefit from a targeted drug called T-DXd. About 70 women with metastatic breast cancer will receive the scan and then treatment, and researchers will compare scan results to how well the cancer responds. If successful, this approach could help doctors choose the most effective therapy for each patient while avoiding unnecessary side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER STAGE IV are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Karolinska University hospital

    RECRUITING

    Solna, 17176, Sweden

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.